Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice

Amel Dudakovic, Emily T. Camilleri, Christopher R. Paradise, Rebekah M. Samsonraj, Martina Gluscevic, Carlo Alberto Paggi, Dana L. Begun, Farzaneh Khani, Oksana Pichurin, Farah S. Ahmed, Ranya Elsayed, Mohammed Elsayed Elsalanty, Meghan Elizabeth McGee Lawrence, Marcel Karperien, Scott M. Riester, Roman Thaler, Jennifer J. Westendorf, Andre J. Van Wijnen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Epigenetic mechanisms control skeletal development and osteoblast differentiation. Pharmacological inhibition of the histone 3 Lys-27 (H3K27) methyltransferase enhancer of zeste homolog 2 (EZH2) in WT mice enhances osteogenesis and stimulates bone formation. However, conditional genetic loss of Ezh2 early in the mesenchymal lineage (i.e. through excision via Prrx1 promoter– driven Cre) causes skeletal abnormalities due to patterning defects. Here, we addressed the key question of whether Ezh2 controls osteoblastogenesis at later developmental stages beyond patterning. We show that Ezh2 loss in committed pre-osteoblasts by Cre expression via the osterix/Sp7 promoter yields phenotypically normal mice. These Ezh2 conditional knock-out mice (Ezh2 cKO) have normal skull bones, clavicles, and long bones but exhibit increased bone marrow adiposity and reduced male body weight. Remarkably, in vivo Ezh2 loss results in a low trabecular bone phenotype in young mice as measured by micro-computed tomography and histomorphometry. Thus, Ezh2 affects bone formation stage-dependently. We further show that Ezh2 loss in bone marrow– derived mesenchymal cells suppresses osteogenic differentiation and impedes cell cycle progression as reflected by decreased metabolic activity, reduced cell numbers, and changes in cell cycle distribution and in expression of cell cycle markers. RNA-Seq analysis of Ezh2 cKO calvaria revealed that the cyclin-dependent kinase inhibitor Cdkn2a is the most prominent cell cycle target of Ezh2. Hence, genetic loss of Ezh2 in mouse pre-osteoblasts inhibits osteogenesis in part by inducing cell cycle changes. Our results suggest that Ezh2 serves a bifunctional role during bone formation by suppressing osteogenic lineage commitment while simultaneously facilitating proliferative expansion of osteoprogenitor cells.

Original languageEnglish (US)
Pages (from-to)12894-12907
Number of pages14
JournalJournal of Biological Chemistry
Volume293
Issue number33
DOIs
StatePublished - Jan 1 2018

Fingerprint

Osteogenesis
Cell Cycle
Bone
Cells
Osteoblasts
Skull
Cyclin-Dependent Kinases
Enhancer of Zeste Homolog 2 Protein
Methyltransferases
Bone Marrow
Histones
Tomography
Bone and Bones
Clavicle
Adiposity
RNA
Epigenomics
Knockout Mice
Defects
Cell Count

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Dudakovic, A., Camilleri, E. T., Paradise, C. R., Samsonraj, R. M., Gluscevic, M., Paggi, C. A., ... Van Wijnen, A. J. (2018). Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice. Journal of Biological Chemistry, 293(33), 12894-12907. https://doi.org/10.1074/jbc.RA118.002983

Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice. / Dudakovic, Amel; Camilleri, Emily T.; Paradise, Christopher R.; Samsonraj, Rebekah M.; Gluscevic, Martina; Paggi, Carlo Alberto; Begun, Dana L.; Khani, Farzaneh; Pichurin, Oksana; Ahmed, Farah S.; Elsayed, Ranya; Elsalanty, Mohammed Elsayed; McGee Lawrence, Meghan Elizabeth; Karperien, Marcel; Riester, Scott M.; Thaler, Roman; Westendorf, Jennifer J.; Van Wijnen, Andre J.

In: Journal of Biological Chemistry, Vol. 293, No. 33, 01.01.2018, p. 12894-12907.

Research output: Contribution to journalArticle

Dudakovic, A, Camilleri, ET, Paradise, CR, Samsonraj, RM, Gluscevic, M, Paggi, CA, Begun, DL, Khani, F, Pichurin, O, Ahmed, FS, Elsayed, R, Elsalanty, ME, McGee Lawrence, ME, Karperien, M, Riester, SM, Thaler, R, Westendorf, JJ & Van Wijnen, AJ 2018, 'Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice', Journal of Biological Chemistry, vol. 293, no. 33, pp. 12894-12907. https://doi.org/10.1074/jbc.RA118.002983
Dudakovic, Amel ; Camilleri, Emily T. ; Paradise, Christopher R. ; Samsonraj, Rebekah M. ; Gluscevic, Martina ; Paggi, Carlo Alberto ; Begun, Dana L. ; Khani, Farzaneh ; Pichurin, Oksana ; Ahmed, Farah S. ; Elsayed, Ranya ; Elsalanty, Mohammed Elsayed ; McGee Lawrence, Meghan Elizabeth ; Karperien, Marcel ; Riester, Scott M. ; Thaler, Roman ; Westendorf, Jennifer J. ; Van Wijnen, Andre J. / Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice. In: Journal of Biological Chemistry. 2018 ; Vol. 293, No. 33. pp. 12894-12907.
@article{4febe8b1b334494994f7171fa4838992,
title = "Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice",
abstract = "Epigenetic mechanisms control skeletal development and osteoblast differentiation. Pharmacological inhibition of the histone 3 Lys-27 (H3K27) methyltransferase enhancer of zeste homolog 2 (EZH2) in WT mice enhances osteogenesis and stimulates bone formation. However, conditional genetic loss of Ezh2 early in the mesenchymal lineage (i.e. through excision via Prrx1 promoter– driven Cre) causes skeletal abnormalities due to patterning defects. Here, we addressed the key question of whether Ezh2 controls osteoblastogenesis at later developmental stages beyond patterning. We show that Ezh2 loss in committed pre-osteoblasts by Cre expression via the osterix/Sp7 promoter yields phenotypically normal mice. These Ezh2 conditional knock-out mice (Ezh2 cKO) have normal skull bones, clavicles, and long bones but exhibit increased bone marrow adiposity and reduced male body weight. Remarkably, in vivo Ezh2 loss results in a low trabecular bone phenotype in young mice as measured by micro-computed tomography and histomorphometry. Thus, Ezh2 affects bone formation stage-dependently. We further show that Ezh2 loss in bone marrow– derived mesenchymal cells suppresses osteogenic differentiation and impedes cell cycle progression as reflected by decreased metabolic activity, reduced cell numbers, and changes in cell cycle distribution and in expression of cell cycle markers. RNA-Seq analysis of Ezh2 cKO calvaria revealed that the cyclin-dependent kinase inhibitor Cdkn2a is the most prominent cell cycle target of Ezh2. Hence, genetic loss of Ezh2 in mouse pre-osteoblasts inhibits osteogenesis in part by inducing cell cycle changes. Our results suggest that Ezh2 serves a bifunctional role during bone formation by suppressing osteogenic lineage commitment while simultaneously facilitating proliferative expansion of osteoprogenitor cells.",
author = "Amel Dudakovic and Camilleri, {Emily T.} and Paradise, {Christopher R.} and Samsonraj, {Rebekah M.} and Martina Gluscevic and Paggi, {Carlo Alberto} and Begun, {Dana L.} and Farzaneh Khani and Oksana Pichurin and Ahmed, {Farah S.} and Ranya Elsayed and Elsalanty, {Mohammed Elsayed} and {McGee Lawrence}, {Meghan Elizabeth} and Marcel Karperien and Riester, {Scott M.} and Roman Thaler and Westendorf, {Jennifer J.} and {Van Wijnen}, {Andre J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1074/jbc.RA118.002983",
language = "English (US)",
volume = "293",
pages = "12894--12907",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "33",

}

TY - JOUR

T1 - Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice

AU - Dudakovic, Amel

AU - Camilleri, Emily T.

AU - Paradise, Christopher R.

AU - Samsonraj, Rebekah M.

AU - Gluscevic, Martina

AU - Paggi, Carlo Alberto

AU - Begun, Dana L.

AU - Khani, Farzaneh

AU - Pichurin, Oksana

AU - Ahmed, Farah S.

AU - Elsayed, Ranya

AU - Elsalanty, Mohammed Elsayed

AU - McGee Lawrence, Meghan Elizabeth

AU - Karperien, Marcel

AU - Riester, Scott M.

AU - Thaler, Roman

AU - Westendorf, Jennifer J.

AU - Van Wijnen, Andre J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Epigenetic mechanisms control skeletal development and osteoblast differentiation. Pharmacological inhibition of the histone 3 Lys-27 (H3K27) methyltransferase enhancer of zeste homolog 2 (EZH2) in WT mice enhances osteogenesis and stimulates bone formation. However, conditional genetic loss of Ezh2 early in the mesenchymal lineage (i.e. through excision via Prrx1 promoter– driven Cre) causes skeletal abnormalities due to patterning defects. Here, we addressed the key question of whether Ezh2 controls osteoblastogenesis at later developmental stages beyond patterning. We show that Ezh2 loss in committed pre-osteoblasts by Cre expression via the osterix/Sp7 promoter yields phenotypically normal mice. These Ezh2 conditional knock-out mice (Ezh2 cKO) have normal skull bones, clavicles, and long bones but exhibit increased bone marrow adiposity and reduced male body weight. Remarkably, in vivo Ezh2 loss results in a low trabecular bone phenotype in young mice as measured by micro-computed tomography and histomorphometry. Thus, Ezh2 affects bone formation stage-dependently. We further show that Ezh2 loss in bone marrow– derived mesenchymal cells suppresses osteogenic differentiation and impedes cell cycle progression as reflected by decreased metabolic activity, reduced cell numbers, and changes in cell cycle distribution and in expression of cell cycle markers. RNA-Seq analysis of Ezh2 cKO calvaria revealed that the cyclin-dependent kinase inhibitor Cdkn2a is the most prominent cell cycle target of Ezh2. Hence, genetic loss of Ezh2 in mouse pre-osteoblasts inhibits osteogenesis in part by inducing cell cycle changes. Our results suggest that Ezh2 serves a bifunctional role during bone formation by suppressing osteogenic lineage commitment while simultaneously facilitating proliferative expansion of osteoprogenitor cells.

AB - Epigenetic mechanisms control skeletal development and osteoblast differentiation. Pharmacological inhibition of the histone 3 Lys-27 (H3K27) methyltransferase enhancer of zeste homolog 2 (EZH2) in WT mice enhances osteogenesis and stimulates bone formation. However, conditional genetic loss of Ezh2 early in the mesenchymal lineage (i.e. through excision via Prrx1 promoter– driven Cre) causes skeletal abnormalities due to patterning defects. Here, we addressed the key question of whether Ezh2 controls osteoblastogenesis at later developmental stages beyond patterning. We show that Ezh2 loss in committed pre-osteoblasts by Cre expression via the osterix/Sp7 promoter yields phenotypically normal mice. These Ezh2 conditional knock-out mice (Ezh2 cKO) have normal skull bones, clavicles, and long bones but exhibit increased bone marrow adiposity and reduced male body weight. Remarkably, in vivo Ezh2 loss results in a low trabecular bone phenotype in young mice as measured by micro-computed tomography and histomorphometry. Thus, Ezh2 affects bone formation stage-dependently. We further show that Ezh2 loss in bone marrow– derived mesenchymal cells suppresses osteogenic differentiation and impedes cell cycle progression as reflected by decreased metabolic activity, reduced cell numbers, and changes in cell cycle distribution and in expression of cell cycle markers. RNA-Seq analysis of Ezh2 cKO calvaria revealed that the cyclin-dependent kinase inhibitor Cdkn2a is the most prominent cell cycle target of Ezh2. Hence, genetic loss of Ezh2 in mouse pre-osteoblasts inhibits osteogenesis in part by inducing cell cycle changes. Our results suggest that Ezh2 serves a bifunctional role during bone formation by suppressing osteogenic lineage commitment while simultaneously facilitating proliferative expansion of osteoprogenitor cells.

UR - http://www.scopus.com/inward/record.url?scp=85051748296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051748296&partnerID=8YFLogxK

U2 - 10.1074/jbc.RA118.002983

DO - 10.1074/jbc.RA118.002983

M3 - Article

VL - 293

SP - 12894

EP - 12907

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 33

ER -